Department of Health and Human Services
Centers for Disease Control and Prevention

Emerging Infectious Diseases

ISSN: 1080-6059

Email this page

Printer-friendly version

Download this article as PDF

Article Contents

The Study
Conclusions
Acknowledgments
References
Figure 1
Figure 2
Table 1
Table 2
Suggested Citation

Volume 12, Number 12–December 2006

Dispatch

Spongiform Encephalopathy in a Miniature Zebu

Torsten Seuberlich,*¹ Catherine Botteron,*¹ Christian Wenker,† Valeria Café-Marçal,* Anna Oevermann,* Bianca Haase,* Tosso Leeb,* Dagmar Heim,‡ and Andreas Zurbriggen*
*University of Berne, Berne, Switzerland; †Zoo Basel, Basel, Switzerland; and ‡Federal Veterinary Office, Berne, Switzerland

The Study

Figure 1

Figure 1. Histopathologic and immunohistochemical analyses. A) Spongiform lesions; B) partially proteinase K–resistant prion protein...

Figure 2

Figure 2. Molecular analyses of the zebu under investigation. Western immunoblot with monoclonal antibodies (MAbs) 6H4 (upper panel) and P4 (lower panel)...

In 2004, a 19-year-old miniature zebu in a zoo in Basel, Switzerland, fell during mating, after which it had abnormal gait and posture. After 6 weeks it started to bump into obstacles and showed anxiety and loss of proprioceptive control. Because of its old age and the progressive course of the disease, the animal was euthanized, and multiple organs were examined postmortem (Table 1). Histopathologic examination showed severe spongiform changes and a moderate gliosis in the brainstem (Figure 1A, nucleus of the solitary tract), and many other CNS structures. Immunohistochemical analysis (6), which used the monoclonal antibodies (MAbs) F99/97.6.1 (VMRD, Pullman, WA, USA) and P4 (R-biopharm, Darmstadt, Germany), identified a marked deposition of PrP^sc in the neuropil (granular type) and the neurons (Figure 1B and 1C). The cerebral cortex contained a moderately increased number of Alzheimer type II cells. Numerous nonnervous tissues, including the lymphoreticular system (Figure 1H), were analyzed by immunohistochemical techniques for the presence of PrP^sc, but none was found. Taken together, these findings led to the diagnosis of a severe SE in combination with a mild metabolic encephalopathy.

To assess the possibility that this animal was infected with the BSE agent, we compared the distribution of the SE-related histopathologic lesions and the PrP^sc deposits in different brain structures of the zebu to those in the brain of a Swiss BSE-affected cow. In both animals, spongiform lesions were similarly distributed throughout the brain, but overall the lesions in the zebu were more severe than those in the cow (Table 2). The depositions of PrP^sc in these structures, as determined by immunohistochemical analysis with MAb F99/97.6.1 and different commercial BSE screening tests (Check Western, Prionics, Zurich, Switzerland; TeSeE, Bio-Rad, Marnes-la-Coquette, France), were well associated with the histopathologic lesions in both animals (data not shown). In comparative Western immunoblot (WB) analysis that used MAb 6H4 (Prionics), the zebu CNS samples (Figure 2, lanes 3 and 5) showed a characteristic 3-band pattern representing un-, mono- and diglycosylated moieties of the proteinase K–resistant PrP^sc fragment. In the zebu these 3 bands clearly showed a migration pattern at a higher molecular mass than that of BSE in the cow (Figure 2, lanes 4 and 6) but similar to a sample from a sheep with scrapie (Figure 2, lane 7). When samples of the same animals were analyzed by WB (Figure 2) and immunohistochemical analysis (Figure 1C–E) with P4, an MAb used to discriminate between BSE and scrapie in sheep (7), PrP^sc was detectable in samples from the sheep with scrapie and the zebu under investigation but not in the cow with BSE. Sequencing of the open reading frame of the Prnp gene of the zebu confirmed that the encoded PrP protein was identical to the B. taurus PrP amino acid sequence (as translated from GenBank accession no. AJ298878).

Conclusions

In 1990, the first case of BSE in cattle in Switzerland was diagnosed; since then, authorities have banned meat and bone meal in ruminant feed in Switzerland. The zebu was born in 1985 and until 1990 ate commercial pellets containing meat and bone meal. Consequently, it might have been exposed to the BSE agent at <5 years of age.

The clinical signs of the zebu were specific for an SE but could have been explained partially by other pathologic findings, e.g., the degenerative lesions of the spine and the metabolic encephalopathy (Table 1). However, prominent spongiform changes and marked depositions of PrP^sc in the brain confirmed the clinical suspicion of an SE. The distribution and type of the lesions (Table 2) and PrP^sc deposits in the brain of the zebu were very similar to those in the brain of the Swiss BSE-affected cow and to findings that have been described previously for BSE in cattle in Switzerland (8,9) and elsewhere (10–12).

In contrast, molecular analysis of PrP^sc clearly showed a difference between the zebu and the BSE cow regarding 1) the apparent molecular mass of the PK-resistant fragment of PrP^sc on WB analysis and 2) the immunoreactivity with MAb P4 on WB and immunohistochemical analyses. Both observations can be explained by extended proteinase K cleavage at the N terminus of PrP^sc in cattle compared with the zebu, resulting in removal of the P4 epitope (7). Recently, very similar molecular findings were reported from France (13) in 3 exceptionally old (8, 10, and 11 years) cattle. These animals had an atypical PrP^sc WB profile, different from that traditionally seen in cattle with BSE but indistinguishable from those in sheep with natural scrapie and cattle with experimental scrapie. This molecular phenotype was retained after transmission of the disease to C57BL/6 mice (14). The authors speculated that their findings may reflect either an infection with another type of infectious agent distinct from BSE, e.g., scrapie, or a sporadic form of SE in cattle. For the zebu, the latter hypothesis is supported by the observation that the molecular features of PrP^sc were similar to the ones observed in type 1 sporadic Creutzfeldt-Jakob disease (15), an SE in humans. On the other hand, consistent with the findings on WB, MAb P4 readily detected PrP^sc by immunohistochemical analyses of the CNS of the zebu and in sheep with scrapie but not in bovine BSE under the conditions used. Extracellular and intracellular PrP^sc was detected by MAb P4 in the zebu and the sheep with scrapie. By contrast, in BSE-affected sheep, PrP^sc was detected by MAb P4 in extracellular but not intracellular space (16). However, further investigations that use comparative pathology and biologic strain typing would be required to characterize the phenotype of SE in this zebu and the infectious agent in more detail.

Whatever the origin of the disease, this case indicates that zebus are not naturally resistant to SE and, therefore, that B. indicus should be included in programs that monitor transmissible spongiform encephalopathies (TSEs) and in risk assessments in countries where these animals are part of the domestic livestock. Although the potential for this disease to cross the species barrier to other animals and humans is not known, zoos and veterinary services should be aware of the possibility of SEs in such animals so they can subsequently minimize the risk for foodborne SE infections in other animal species (especially Felidae) and humans by removing specified risk materials.

Acknowledgments

We thank Doris Ambühl, Valérie Juillerat, and Christoph Prisi for excellent technical support.

This work was financed with resources provided by the Swiss Federal Veterinary Office.

Dr Seuberlich is a veterinarian and head of the TSE rapid test division in the Swiss reference laboratory for TSE in animals. His major research interests include the diagnosis and molecular characterization of emerging TSE agents.

References

Wyatt JM, Pearson GR, Smerdon TN, Gruffydd-Jones TJ, Wells GA. Spongiform encephalopathy in a cat [letter]. Vet Rec. 1990;126:513.
Eliot M, Adjou KT, Coulpier M, Fontaine JJ, Hamel R, Lilin T, et al. BSE agent signatures in a goat [letter]. Vet Rec. 2005;156:523–4. Erratum in Vet Rec. 2005;156:620.
Bons N, Mestre-Frances N, Belli P, Cathala F, Gajdusek DC, Brown P. Natural and experimental oral infection of nonhuman primates by bovine spongiform encephalopathy agents. Proc Natl Acad Sci U S A. 1999;96:4046–51.
Heim D, Geiser F, Perler L, Wyss R. Beyond BSE: Transmissible spongiform encephalopathies in other animal species [Article in German]. Schweiz Arch Tierheilkd. 2002;144:664–73.
Kirkwood JK, Cunningham AA. Epidemiological observations on spongiform encephalopathies in captive wild animals in the British Isles. Vet Rec. 1994;135:296–303.
Organisation Mondiale de la Santé Animale. Manual of diagnostic tests and vaccines for terrestrial animals. 5th ed. 2004. [cited 2006 Oct 11]. Available from http://www.oie.int
Stack MJ, Chaplin MJ, Clark J. Differentiation of prion protein glycoforms from naturally occurring sheep scrapie, sheep-passaged scrapie strains (CH1641 and SSBP1), bovine spongiform encephalopathy (BSE) cases and Romney and Cheviot breed sheep experimentally inoculated with BSE using two monoclonal antibodies. Acta Neuropathol (Berl). 2002;104:279–86.
Fatzer R, Graber HU, Meyer RK, Cardozo C, Vandevelde M, Zurbriggen A. Neuronal degeneration in brain stem nuclei in bovine spongiform encephalopathy. Zentralbl Veterinarmed A. 1996;43:23–9.
Graber HU, Meyer RK, Fatzer R, Vandevelde M, Zurbriggen A. In situ hybridization and immunohistochemistry for prion protein (PrP) in bovine spongiform encephalopathy (BSE). Zentralbl Veterinarmed A. 1995;42:453–9.
Casalone C, Caramelli M, Crescio MI, Spencer YI, Simmons MM. BSE immunohistochemical patterns in the brainstem: a comparison between UK and Italian cases. Acta Neuropathol (Berl). 2006;111:444–9.
Simmons MM, Harris P, Jeffrey M, Meek SC, Blamire IW, Wells GA. BSE in Great Britain: consistency of the neurohistopathological findings in two random annual samples of clinically suspect cases. Vet Rec. 1996;138:175–7.
Wells GA, Wilesmith JW. The neuropathology and epidemiology of bovine spongiform encephalopathy. Brain Pathol. 1995;5:91–103.
Biacabe AG, Laplanche JL, Ryder S, Baron T. Distinct molecular phenotypes in bovine prion diseases. EMBO Rep. 2004;5:110–5.
Baron TG, Biacabe AG, Bencsik A, Langeveld JP. Transmission of new bovine prion to mice. Emerg Infect Dis. 2006;12:1125–8.
Parchi P, Castellani R, Capellari S, Ghetti B, Young K, Chen SG, et al. Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol. 1996;39:767–78.
Jeffrey M, Martin S, Gonzalez L, Ryder SJ, Bellworthy SJ, Jackman R. Differential diagnosis of infections with the bovine spongiform encephalopathy (BSE) and scrapie agents in sheep. J Comp Pathol. 2001;125:271–84.

Figures

Figure 1. Histopathologic and immunohistochemical analyses. A) Spongiform lesions; B) partially proteinase K–resistant prion protein...
Figure 2. Molecular analyses of the zebu under investigation. Western immunoblot with monoclonal antibodies (MAbs) 6H4 (upper panel) and P4 (lower panel)...

Tables

Table 1. Pathologic findings in a zebu with spongiform encephalopathy, Switzerland, 2004
Table 2. Histopathologic lesions in brain of zebu with spongiform encephalopathy and cow with bovine spongiform encephalopathy, Switzerland, 2004